| Nov 23, 2011 | |
CIC microGUNE and Biodonostia test a new technique for evaluating intestinal diseases in patients |
|
| (Nanowerk News) The CIC microGUNE research centre and the Biodonostia Institute have recently started testing a new technique for assessing the severity of inflammatory intestinal diseases, such as Crohn's Disease, in patients at the Donostia Hospital. | |
| This new technology, which has been developed jointly by the two centres, involves detection of the TNF-alpha protein, which is known to be a marker for numerous inflammatory diseases such as Crohn's Disease, rheumatoid arthritis and spondylitis. | |
 |
|
| CIC microGUNE and Biodonostia test a new technique for evaluating intestinal diseases in patients. | |
| The excellent results obtained to date could lead to CIC microGUNE and Biodonostia patenting this technology as it could be used to detect markers for other diseases by making a few modifications. | |
| In contrast to current methods for diagnosing Crohn's Disease, such as endoscopy, the TNF-alpha detection technique developed by CIC microGUNE and Biodonostia is essentially non-invasive as it only requires a small amount of blood. | |
| Subsequent development of this technique is expected to lead to deposition of the blood sample on a microdevice incorporated into a credit card-sized support. This support will then be introduced into a reader, which will provide the diagnosis in only a few minutes. Furthermore, it has the advantage of being able to determine the severity of the disease much more accurately. |
| Source: CIC microGUNE |
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.